Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 3-12

  Mahendra, Ankit ^a,b,c   Padiolleau Lefevre, Séverine ^d   Kaveri, Srinivas V ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Acquired haemophilia A; Catalytic antibodies; Factor IX; Factor VIII; Factor VIII inhibitors

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY; VON WILLEBRAND FACTOR;

ALLOIMMUNITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CTLA4 GENE; F8 GENE; GENETIC POLYMORPHISM; HAPLOTYPE; HEMOPHILIA A; HUMAN; HYDROLYSIS; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; SUBSTITUTION THERAPY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; EPITOPES; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; PROTEOLYSIS; RISK FACTORS; T-LYMPHOCYTES;

EID: 83555172287     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08890.x     Document Type: Review

References (83)

1. Algiman, M., Dietrich, G., Nydegger, U., Boieldieu, D., Sultan, Y. & Kazatchkine, M.D. (1992) Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proceedings of the National Academy of Sciences of the United States of America, 89, 3795-3799.
2. Arai, M., Scandella, D. & Hoyer, L.W. (1989) Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. Journal of Clinical Investigation, 83, 1978-1984.
3. Astermark, J., Oldenburg, J., Carlson, J., Pavlova, A., Kavakli, K., Berntorp, E. & Lefvert, A.K. (2006a) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood, 108, 3739-3745.
4. Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E. & Lefvert, A.K. (2006b) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood, 107, 3167-3172.
5. Astermark, J., Wang, X., Oldenburg, J., Berntorp, E. & Lefvert, A.K. (2007) Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 5, 263-265.
6. Avalle, B., Thomas, D. & Friboulet, A. (1998) Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams. FASEB Journal, 12, 1055-1060.
7. Baranovskii, A.G., Ershova, N.A., Buneva, V.N., Kanyshkova, T.G., Mogelnitskii, A.S., Doronin, B.M., Boiko, A.N., Gusev, E.I., Favorova, O.O. & Nevinsky, G.A. (2001) Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. Immunology Letters, 76, 163-167.
8. Boggio, L.N. & Green, D. (2001) Acquired hemophilia. Reviews in Clinical and Experimental Hematology, 5, 389-404.
9. van den Brink, E.N., Turenhout, E.A., Davies, J., Bovenschen, N., Fijnvandraat, K., Ouwehand, W.H., Peters, M. & Voorberg, J. (2000a) Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood, 95, 558-563.
10. van den Brink, E., Turenhout, E., Bank, C., Fijnvandraat, K., Peters, M. & Voorberg, J. (2000b) Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood, 96, 540-545.
11. van den Brink, E., Turenhout, E., Bovenschen, N., Heijnen, B., Mertens, K., Peters, M. & Voorberg, J. (2001) Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VII. Blood, 97, 966-972.
12. van den Brink, E.N., Bril, W.S., Turenhout, E.A., Zuurveld, M., Bovenschen, N., Peters, M., Yee, T.T., Mertens, K., Lewis, D.A., Ortel, T.L., Lollar, P., Scandella, D. & Voorberg, J. (2002) Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood, 99, 2828-2834.
13. Castaldi, P.A. & Penny, R. (1970) A macroglobulin with inhibitory activity against coagulation factor VIII. Blood, 35, 370-376.
14. Collins, P.W., Hirsch, S., Baglin, T.P., Dolan, G., Hanley, J., Makris, M., Keeling, D.M., Liesner, R., Brown, S.A. & Hay, C.R. (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 109, 1870-1877.
15. Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Güngör, T., Krackhardt, B. & Kornhuber, B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594-598.
16. Fay, P.J. & Scandella, D. (1999) Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. The Journal of Biological Chemistry, 274, 29826-29830.
17. Franchini, M. (2006) Haemostasis and pregnancy. Thrombosis and Haemostasis, 95, 401-413.
18. Friboulet, A., Avalle, B., Debat, H. & Thomas, D. (1999) A possible role of catalytic antibodies in metabolism. Immunology Today, 20, 474-475.
19. Fulcher, C.A., de Graaf Mahoney, S. & Zimmerman, T.S. (1987) Factor VIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood, 69, 1475-1480.
20. Gawryl, M.S. & Hoyer, L.W. (1982) Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood, 60, 1103-1109.
21. Gharagozlou, S., Sharifian, R.A., Khoshnoodi, J., Karimi, K., Milani, M., Okita, D.K., Shokri, F. & Conti-Fine, B.M. (2009) Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thrombosis and Haemostasis, 101, 834-839.
22. Gilles, J.G., Grailly, S.C., De Maeyer, M., Jacquemin, M.G., VanderElst, L.P. & Saint-Remy, J.M. (2004) In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood, 103, 2617-2623.
23. Glueck, H.I. & Hong, R. (1965) A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin. Journal of Clinical Investigation, 44, 1866-1881.
24. Glueck, H.I., Coots, M.C., Benson, M., Dwulet, F.E. & Hurtubise, P.E. (1989) A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization. Journal of Laboratory and Clinical Medicine, 113, 269-277.
25. Green, D. & Lechner, K. (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thrombosis and Haemostasis, 45, 200-203.
26. Holme, P.A., Brosstad, F. & Tjonnfjord, G.E. (2005) Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia, 11, 510-515.
27. Hwang, S.H., Lim, J.A., Kim, H.C., Lee, H.W. & Kim, H.S. (2011) Identification of a shared F8 mutation in the Korean patients with acquired hemophilia A. The Korean Journal of Hematology, 46, 49-51.
28. Izadyar, L., Friboulet, A., Remy, M.H., Roseto, A. & Thomas, D. (1993) Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proceedings of the National Academy of Sciences of the United States of America, 90, 8876-8880.
29. Jacquemin, M.G., Desqueper, B.G., Benhida, A., Vander Elst, L., Hoylaerts, M.F., Bakkus, M., Thielemans, K., Arnout, J., Peerlinck, K., Gilles, J.G., Vermylen, J. & Saint-Remy, J.M. (1998) Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92, 496-506.
30. Jacquemin, M., Benhida, A., Peerlinck, K., Desqueper, B., Vander Elst, L., Lavend'homme, R., d'Oiron, R., Schwaab, R., Bakkus, M., Thielemans, K., Gilles, J.G., Vermylen, J. & Saint-Remy, J.M. (2000) A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von willebrand factor. Blood, 95, 156-163.
31. Kalaga, R., Li, L., O'Dell, J.R. & Paul, S. (1995) Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. Journal of Immunology, 155, 2695-2702.
32. Kamate, C., Lenting, P.J., van den Berg, H.M. & Mutis, T. (2006) Depletion of CD4(+)CD25(high) regulatory T cells may enhance or uncover factor VIII-specific T cell responses in healthy individuals. Journal of Thrombosis and Haemostasis, 5, 611-613.
33. Kazatchkine, M.D., Lacroix-Desmazes, S., Moreau, A. & Kaveri, S.V. (2000) Idiotypic regulation of anti-factor VIII antibodies. Haematologica, 85, 97-99.
34. Lacroix-Desmazes, S., Moreau, A., Sooryanarayana, Bonnemain, C., Stieltjes, N., Pashov, A., Sultan, Y., Hoebeke, J., Kazatchkine, M.D. & Kaveri, S.V. (1999) Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nature Medicine, 5, 1044-1047.
35. Lacroix-Desmazes, S., Moreau, A., Pashov, A., Sooryanarayana, Stahl, D., Saint-Remy, J.M., Kaveri, S.V. & Kazatchkine, M.D. (2000) Natural antibodies to factor VIII. Seminars in Thrombosis and Hemostasis, 26, 157-165.
36. Lacroix-Desmazes, S., Bayry, J., Misra, N., Horn, M.P., Villard, S., Pashov, A., Stieltjes, N., d'Oiron, R., Saint-Remy, J.M., Hoebeke, J., Kazatchkine, M.D., Reinbolt, J., Mohanty, D. & Kaveri, S.V. (2002) The prevalence of proteolytic antibodies against factor VIII in hemophilia A. New England Journal of Medicine, 346, 662-667.
37. Lacroix-Desmazes, S., Bayry, J., Kaveri, S.V., Hayon-Sonsino, D., Thorenoor, N., Charpentier, J., Luyt, C.E., Mira, J.P., Nagaraja, V., Kazatchkine, M.D., Dhainaut, J.F. & Mallet, V.O. (2005) High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 102, 4109-4113.
38. Lacroix-Desmazes, S., Wootla, B., Delignat, S., Dasgupta, S., Nagaraja, V., Kazatchkine, M.D. & Kaveri, S.V. (2006a) Pathophysiology of catalytic antibodies. Immunology Letters, 103, 3-7.
39. Lacroix-Desmazes, S., Wootla, B., Dasgupta, S., Delignat, S., Bayry, J., Reinbolt, J., Hoebeke, J., Saenko, E., Kazatchkine, M.D., Friboulet, A., Christophe, O., Nagaraja, V. & Kaveri, S.V. (2006b) Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. Journal of Immunology, 177, 1355-1363.
40. Li, L., Paul, S., Tyutyulkova, S., Kazatchkine, M.D. & Kaveri, S. (1995) Catalytic activity of anti-thyroglobulin antibodies. Journal of Immunology, 154, 3328-3332.
41. Ligers, A., Teleshova, N., Masterman, T., Huang, W.X. & Hillert, J. (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes and Immunity, 2, 145-152.
42. Maurer, M., Loserth, S., Kolb-Maurer, A., Ponath, A., Wiese, S., Kruse, N. & Rieckmann, P. (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics, 54, 1-8.
43. Meeks, S.L., Healey, J.F., Parker, E.T., Barrow, R.T. & Lollar, P. (2007) Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood, 110, 4234-4242.
44. Meeks, S.L., Healey, J.F., Parker, E.T., Barrow, R.T. & Lollar, P. (2008) Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood, 112, 1151-1153.
45. Moreau, A., Lacroix-Desmazes, S., Stieltjes, N., Saenko, E., Kaveri, S.V., d'Oiron, R., Sultan, Y., Scandella, D. & Kazatchkine, M.D. (2000) Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity, are present in the plasma of non-responder patients with severe hemophilia A and healthy blood donors. Blood, 95, 3435-3441.
46. Nardi, M., Tomlinson, S., Greco, M.A. & Karpatkin, S. (2001) Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell, 106, 551-561.
47. Nathan, C. (2002) Immunology. Catalytic antibody bridges innate and adaptive immunity. Science, 298, 2143-2144.
48. Paul, S., Volle, D.J., Beach, C.M., Johnson, D.R., Powell, M.J. & Massey, R.J. (1989) Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science, 244, 1158-1162.
49. Paul, S., Li, L., Kalaga, R., Wilkins-Stevens, P., Stevens, F.J. & Solomon, A. (1995) Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragments. The Journal of Biological Chemistry, 270, 15257-15261.
50. Paul, S., Planque, S., Zhou, Y.X., Taguchi, H., Bhatia, G., Karle, S., Hanson, C. & Nishiyama, Y. (2003) Specific HIV gp120 cleaving antibodies induced by covalently reactive analog of gp120. The Journal of Biological Chemistry, 278, 20429-20435.
51. Pauling, L. (1946) Molecular architecture and biological reactions. Chemical and Engineering News, 34, 1375-1377.
52. Pavlova, A., Diaz-Lacava, A., Zeitler, H., Satoguina, J., Niemann, B., Krause, M., Scharrer, I., Hoerauf, A., Wienker, T. & Oldenburg, J. (2008) Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia, 14, 355-360.
53. Pavlova, A., Delev, D., Lacroix-Desmazes, S., Schwaab, R., Mende, M., Fimmers, R., Astermark, J. & Oldenburg, J. (2009) Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. Journal of Thrombosis and Haemostasis, 7, 2006-2015.
54. Pavlova, A., Zeitler, H., Scharrer, I., Brackmann, H.H. & Oldenburg, J. (2010) HLA genotype in patients with acquired haemophilia A. Haemophilia, 16, 107-112.
55. Peerlinck, K., Jacquemin, M., Arnout, J., Hoylaerts, M., Gilles, J., Lavend'homme, R., Johnson, K., Freson, K., Scandella, D., Saint-Remy, J.-M. & Vermylen, J. (1999) Antifactor VIII Antibody Inhibiting Allogeneic but not Autologous Factor VIII in patients with mild hemophilia A. Blood, 93, 2267-2273.
56. Planque, S., Bangale, Y., Song, X.T., Karle, S., Taguchi, H., Poindexter, B., Bick, R., Edmundson, A., Nishiyama, Y. & Paul, S. (2004) Ontogeny of proteolytic immunity: IgM serine proteases. The Journal of Biological Chemistry, 279, 14024-14032.
57. Pollack, S.J., Jacobs, J.W. & Schultz, P.G. (1986) Selective chemical catalysis by an antibody. Science, 234, 1570.
58. Ponomarenko, N.A., Durova, O.M., Vorobiev, I.I., Aleksandrova, E.S., Telegin, G.B., Chamborant, O.G., Sidorik, L.L., Suchkov, S.V., Alekberova, Z.S., Gnuchev, N.V. & Gabibov, A.G. (2002) Catalytic antibodies in clinical and experimental pathology: human and mouse models. Journal of Immunological Methods, 269, 197-211.
59. Ponomarenko, N.A., Pillet, D., Paon, M., Vorobiev, I.I., Smirnov, I.V., Adenier, H., Avalle, B., Kolesnikov, A.V., Kozyr, A.V., Thomas, D., Gabibov, A.G. & Friboulet, A. (2007) Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry, 46, 14598-14609.
60. Prescott, R., Nakai, H., Saenko, E.L., Scharrer, I., Nilsson, I.M., Humphries, J.E., Hurst, D., Bray, G. & Scandella, D. (1997) The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood, 89, 3663-3671.
61. Reding, M.T., Wu, H., Krampf, M., Okita, D.K., Diethelm-Okita, B.M., Key, N.S. & Conti-Fine, B.M. (1999) CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thrombosis and Haemostasis, 82, 509-515.
62. Reding, M., Wu, H., Krampf, M., Okita, D., Diethelm-Okita, B., Christie, B., Key, N. & Conti-Fine, B. (2000) Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thrombosis and Haemostasis, 84, 643-652.
63. Reding, M.T., Lei, S., Lei, H., Green, D., Gill, J. & Conti-Fine, B.M. (2002) Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in congenital and acquired hemophilia patients. Thrombosis and Haemostasis, 88, 568-575.
64. Reding, M.T., Okita, D.K., Diethelm-Okita, B.M., Anderson, T.A. & Conti-Fine, B.M. (2003) Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. Journal of Thrombosis and Haemostasis, 1, 1777-1784.
65. Reding, M.T., Okita, D.K., Diethelm-Okita, B.M., Anderson, T.A. & Conti-Fine, B.M. (2004) Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. Journal of Thrombosis and Haemostasis, 2, 1385-1394.
66. Rossi, F., Sultan, Y. & Kazatchkine, M.D. (1988) Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clinical and Experimental Immunology, 74, 311-316.
67. Sallah, S., Nguyen, N.P., Abdallah, J.M. & Hanrahan, L.R. (2000) Acquired hemophilia in patients with hematologic malignancies. Archives of Pathology and Laboratory Medicine, 124, 730-734.
68. de la Salle, C., Charmantier, J.L., Baas, M.J., Schwartz, A., Wiesel, M.L., Grunebaum, L. & Cazenave, J.P. (1993) A deletion located in the 3′ non translated part of the factor IX gene responsible for mild haemophilia B. Thrombosis and Haemostasis, 70, 370-371.
69. Sari, I., Erkurt, M.A., Ifran, A., Kaptan, K. & Beyan, C. (2009) Multiple myeloma presenting with acquired factor VIII inhibitor. International Journal of Hematology, 90, 166-169.
70. Satterthwait, A.C. & Jencks, W.P. (1974) The mechanism of the aminolysis of acetate esters. Journal of the American Chemical Society, 96, 7018-7031.
71. Scandella, D. (1999) Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sanguinis, 77(Suppl. 1), 17-20.
72. Shuster, A.M., Gololobov, G.V., Kvashuk, O.A., Bogomolova, A.E., Smirnov, I.V. & Gabibov, A.G. (1992) DNA hydrolyzing autoantibodies. Science, 256, 665-667.
73. Taguchi, H., Planque, S., Sapparapu, G., Boivin, S., Hara, M., Nishiyama, Y. & Paul, S. (2008) Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. The Journal of Biological Chemistry, 283, 36724-36733.
74. Thomas, N.R. (1994) Hapten design for the generation of catalytic antibodies. Applied Biochemistry and Biotechnology, 47, 345-372.
75. Tramontano, A., Janda, K.D. & Lerner, R.A. (1986) Catalytic antibodies. Science, 234, 1566.
76. Viel, K.R., Ameri, A., Abshire, T.C., Iyer, R.V., Watts, R.G., Lutcher, C., Channell, C., Cole, S.A., Fernstrom, K.M., Nakaya, S., Kasper, C.K., Thompson, A.R., Almasy, L. & Howard, T.E. (2009) Inhibitors of Factor VIII in black patients with hemophilia. New England Journal of Medicine, 360, 1618-1627.
77. Wentworth, J.P., McDunn, J.E., Wentworth, A.D., Takeuchi, C., Nieva, J., Jones, T., Bautista, C., Ruedi, J.M., Gutierrez, A., Janda, K.D., Babior, B.M., Eschenmoser, A. & Lerner, R.A. (2002) Evidence of antibody-catalyzed ozone formation in bacterial killing and inflammation. Science, 298, 2195-2199.
78. Wilson, A.G., Symons, J.A., McDowell, T.L., McDevitt, H.O. & Duff, G.W. (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America, 94, 3195-3199.
79. Wootla, B., Dasgupta, S., Dimitrov, J.D., Bayry, J., Levesque, H., Borg, J.Y., Borel-Derlon, A., Rao, D.N., Friboulet, A., Kaveri, S.V. & Lacroix-Desmazes, S. (2008) Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. Journal of Immunology, 180, 7714-7720.
80. Wootla, B., Mahendra, A., Dimitrov, J.D., Friboulet, A., Borel-Derlon, A., Rao, D.N., Uda, T., Borg, J.Y., Bayry, J., Kaveri, S.V. & Lacroix-Desmazes, S. (2009) Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters, 583, 2565-2572.
81. Wootla, B., Christophe, O.D., Mahendra, A., Dimitrov, J.D., Repesse, Y., Ollivier, V., Friboulet, A., Borel-Derlon, A., Levesque, H., Borg, J.Y., Andre, S., Bayry, J., Calvez, T., Kaveri, S.V. & Lacroix-Desmazes, S. (2011) Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 117, 2257-2264.
82. Yee, T.T., Taher, A., Pasi, K.J. & Lee, C.A. (2000) A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clinical & Laboratory Haematology, 22, 275-278.
83. Zheng, C., Huang, D., Liu, L., Wu, R., Bergenbrant Glas, S., Osterborg, A., Bjorkholm, M., Holm, G., Yi, Q. & Sundblad, A. (2001) Interleukin-10 gene promoter polymorphisms in multiple myeloma. International Journal of Cancer, 95, 184-188.